IGF-1 LR3

Two Receptors Close Enough to Form Hybrids

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

The IGF-1 receptor and the insulin receptor are structurally related, and cells expressing both can assemble hybrid receptors containing subunits of each. That relatedness means neither ligand is entirely selective for its own receptor.

Key facts

Relationship
Structurally homologous receptors
Hybrids
Contain subunits of both
Consequence
Selectivity is relative, not absolute
Chimeric receptor work
Schäffer 1993 (PMID 8428981)
Journal
J Biol Chem, 15 February 1993
Practical relevance
Glucose handling, oncology targeting

Why the two receptors resemble each other

Insulin and IGF-1 are themselves structurally related, as the name insulin-like growth factor records directly. Both descend from a common ancestral system, and their receptors descend alongside them. Shared ancestry produces shared architecture, and shared architecture produces overlapping ligand recognition.

What a hybrid receptor is

Both receptors assemble from subunit pairs. In a cell expressing both, assembly can mix them, producing a receptor with one half from each. Hybrids have their own binding characteristics, distinct from either parent receptor, and their abundance depends on the relative expression of the two in that cell. The pharmacology therefore becomes cell-type dependent.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £49.99

How the relationships were mapped

By building chimeric receptors and hybrid ligands and testing which combinations bind. Schäffer and colleagues examined interactions of a hybrid insulin and IGF-I analogue with chimeric insulin and type I IGF receptors in the Journal of Biological Chemistry in 1993. Swapping defined regions between two related molecules and observing what changes is how the determinants of selectivity get identified.

Why this matters for glucose

IGF-1 engaging insulin receptors, or hybrids, produces insulin-like metabolic effects. That is a documented property of the system rather than a hypothetical, and it means anything raising free IGF-1 availability has a route to affecting glucose handling that is separate from its growth-related effects.

Why it complicated the oncology programmes

Blocking IGF-1R without touching insulin receptors or hybrids is difficult because of the structural similarity. That is one of the reasons anti-IGF-1R development proved harder than the biology suggested. The target could not be engaged cleanly, and disturbing insulin signalling has immediate consequences.

What follows for an engineered analogue

An analogue designed to increase free IGF-1 increases engagement of whatever that free IGF-1 reaches, which includes insulin receptors and hybrids in proportion to their local abundance. Selectivity is a property of the receptor landscape as much as of the molecule, and it cannot be fully specified from the sequence alone.

Frequently asked questions

Why does this matter?

It means selectivity is relative. IGF-1 engaging insulin receptors or hybrids produces insulin-like metabolic effects, and it complicated IGF-1R oncology targeting.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More IGF-1 LR3 articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.